Last week, the FDA announced approval of the Medtronic 670G, which is considered by some to be the first pump system worthy of the label of artificial pancreas. However, the 670G still requires a fair amount of user input, and there are other artificial pancreas pump systems in clinical trials that may offer the promise […]
Clinton has made drug price control more of a central issue in her campaign (although it should be said that neither candidate has put the issue on the front burner). For this article, we will focus on her proposal, and what it’s chances are of creating reform.
Believe it or not, some people were disappointed and underwhelmed by solid evidence that Victoza (ligratude), a medication for type 2 diabetes, reduces the risk of fatal diabetes complications. That news, based on a massive clinical trial of Novo Nordisk’s drug, was one of the mostly widely reported items from the American Diabetes Association’s recent […]
Last month, a major scientific journal published an unprecedented three papers from the congress, including “New Insulin Delivery Recommendations” from the 183 doctors, nurses, educators, and conference attendees in Rome. The publications are based on results of what is probably the largest survey ever done concerning insulin injection technique in more than 13,000 insulin-injecting people […]
Curious what’s coming? Read on for a summary of the insulin delivery and glucose monitoring devices expected to launch in the US by mid-2017 or earlier, based on the most recent company timelines (listed chronologically). This list is not fully comprehensive, but does cover the major device launches expected.
In June 2016, JDRF and MannKind announced a research and clinical trial collaboration which will focus upon Afrezza’s safety and effectiveness for pediatric use. This will help Mannkind fulfill commitments the company has made to the FDA to do more testing of the product.
No sooner did news break that the FDA had approved the Medtronic 670G did debate start over whether it deserved to be labeled an artificial pancreas. I wanted to provide my thoughts on why as the editorial director of a diabetes news publication, I felt comfortable using the term for this hybrid automated pump-and-CGM system.
A novel treatment meant to stop Type 1 diabetes by increasing the number of T cells in the body is being given special attention by the FDA. The treatment, called CLBS03, has recently been granted Fast Track status by federal regulators, a designation which speeds up the approval process.
New research suggests that taking painkillers known as non-steroidal anti-inflammatory drugs (NSAIDs) – which includes ibuprofen – increases the risk of heart failure by less than 20% overall. NSAIDs are a group of painkilling medicines commonly taken by people with joint problems, backache and arthritis. They are prescribed to relieve pain and reduce inflammation.
The device — Medtronic’s MiniMed 670G — is what’s known as a hybrid closed-loop system. That means it monitors blood sugar and then delivers necessary background (also known as basal) insulin doses. The device will also shut off when blood sugar levels drop too low.
The Bigfoot system, built upon Asante technology, has three components – the pump body, the Dexcom G5 CGM and a controller. The body is a single-use, disposable piece that contains a battery and a 3-mililiter cartridge of Humalog. The Dexcom G5 sends glucose readings to the controller, which is the brains of the operation. The […]
A combination of factors makes it more difficult for the immune systems of people older than 65 to respond to the vaccination, she says, and the protective effect may also wear off faster than it does in young people.
This study, published in Diabetologia followed up on the 1993 Steno-2 study. In the Steno-2 a group of 160 people with type 2 diabetes were randomized and treated with either a conventional treatment plan or an intensified treatment plan. The initial study ended after eight years.
Diabetes Care, the journal of the American Diabetes Association, published a statement after the 2nd Diabetes Surgery Summit (DSS-II) recognizing metabolic (bariatric) surgery as a standard and safe treatment option for some people with type 2 diabetes.
The BCG vaccine is currently in phase II of a five-year trial, testing the vaccine’s effects on human patients. But lead researcher Dr. Denise Faustman, M.D, Ph.D., is optimistic of the vaccine’s ability to help people. As she said in an interview with Diabetes in Control, “We’re talking about a considerable number of people, 10 […]
Novo Nordisk voluntarily recalled six batches of its GlucaGen HypoKit (glucagon for injection) on September 9, 2016. Two reports out of Europe detailed malfunction of needles on the syringe containing Sterile Water for Injection (SWFI) – an essential component of the kit.
A study presented at a scientific congress Thursday reported a link between long naps and a higher risk of diabetes, though it couldn’t say if daytime sleeping was a symptom or a cause. People who slept more than an hour each day were 45 percent more likely to develop type 2 diabetes, a debilitating condition […]
A few years ago, Richard Kahn, the now-retired chief scientific and medical officer of the American Diabetes Association, was charged with organizing a committee to prescribe a diet plan for people with diabetes. He began by looking at the evidence for different diets, asking which, if any, best controlled diabetes.
In his book, Think Like A Pancreas: A Practical Guide to Managing Diabetes With Insulin, certified diabetes educator Gary Scheiner devotes a chapter on the basics of insulin pump therapy. While studies show that pump therapy, when done right, leads to better blood sugar control, it’s not for everyone. Scheiner gives a concise pro/con list […]
Cat-scratch disease, as the name suggests, is spread by cats. It’s long been considered a mild illness, but a study finds that people are getting more serious complications, which can be fatal. And kissing kittens increases the risk of being infected.